other material
confidence high
sentiment positive
materiality 0.70
Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms
Phathom Pharmaceuticals, Inc.
- At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).
- Median heartburn-free nights: 70.4% (10 mg), 71.0% (20 mg), 45.5% (placebo) over 4 weeks.
- Separation from placebo observed after first dose: 45.3% (10 mg) and 52.4% (20 mg) heartburn-free night vs 32.1% placebo.
- Symptom relief sustained through 20-week active extension; median heartburn-free nights remained above 70%.
- VOQUEZNA generally well tolerated; most common AEs (≤5%) included URI, sinusitis, influenza, UTI, nausea.